DEVELOPMENTAL FUNDS ABSTRACT The Developmental funds of the CCSG represent a vital component of the UAB-CCC Core grant by empowering the Center Director to respond to and provide leadership for the strategic scientific needs and priorities of the Center. The UAB CCC uses these funds in three primary ways. First, New Investigator funds are combined with other Center funds (e.g., gift account) and funds from departments and other Centers to provide attractive recruitment packages for faculty important to the Cancer Center's research enterprise. These recruitments may represent an enhancement of a new research initiative, expansion of an existing program or replacement of departing or retiring faculty. During the current cycle the recruited investigators have been awarded over $1.9M in extramural funding. The second use of these funds is for our Pilot Grant Program with an emphasis on young or new faculty and inter- and intra-programmatic collaborative research programs and seed funding for multi-project grants such as SPOREs and P01s. The CCC contributes to 3-4 junior faculty grants in collaboration with our American Cancer Society Institutional Research Grant. Our Scientific Advisory Committee reviews and critiques these applications for Cancer Center research priorities and potential for extramural funding. The recipients of these funds have an excellent track record of successful grant funding (more than $4.1M in extramural direct costs) and adding to the scientific growth of our programs. Third, development funding is used to invest in new research technologies that the Center membership find of significant value yet cannot afford to implement individually. This investment manifests itself as expansion of the capabilities of a current shared facility or the creation of a developing shared facilities centered on the new technology. In the current funding cycle the Microbiome/Gnotobiotic Shared Facility received Developmental Funds as did the Pharamacometrics facility During the last funding cycle of the UAB-CCC there were five new investigators supported by CCSG Development dollars, seven junior investigators received pilot funding, 6 putative PO1 teams received developmental funding, one new developing shared facility was started, and another four received significant upgrades in technology. All the efforts of the CCSG Development dollars were implemented to further the mission of the Center and provide added value to the CCC membership.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA013148-46S1
Application #
9674342
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Belin, Precilla L
Project Start
Project End
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
46
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Williams, Adele P; Waters, Alicia M; Stewart, Jerry E et al. (2018) A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro. J Surg Res 228:54-62
Carson, Tiffany L; Wang, Fuchenchu; Cui, Xiangqin et al. (2018) Associations Between Race, Perceived Psychological Stress, and the Gut Microbiota in a Sample of Generally Healthy Black and White Women: A Pilot Study on the Role of Race and Perceived Psychological Stress. Psychosom Med 80:640-648
McCaw, Tyler R; Randall, Troy D; Arend, Rebecca C (2018) Overcoming immune suppression with epigenetic modification in ovarian cancer. Transl Res :
Frugé, Andrew D; Cases, Mallory G; Howell, Carrie R et al. (2018) Fingernail and toenail clippings as a non-invasive measure of chronic cortisol levels in adult cancer survivors. Cancer Causes Control 29:185-191
Samykutty, Abhilash; Grizzle, William E; Fouts, Benjamin L et al. (2018) Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle. Biomaterials 182:114-126
Geng, Mengxin; Austin, Frank; Shin, Ronald et al. (2018) Covalent Structure and Bioactivity of the Type AII Lantibiotic Salivaricin A2. Appl Environ Microbiol 84:
Powell, T Clark; Dilley, Sarah E; Bae, Sejong et al. (2018) The Impact of Racial, Geographic, and Socioeconomic Risk Factors on the Development of Advanced-Stage Cervical Cancer. J Low Genit Tract Dis 22:269-273
Friedman, Gregory K; Bernstock, Joshua D; Chen, Dongquan et al. (2018) Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Sci Rep 8:13930
Subramaniam, Akila; Blanchard, Christina T; Erickson, Britt K et al. (2018) Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol 132:20-27
Kasten, Benjamin B; Oliver, Patsy G; Kim, Harrison et al. (2018) 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci 19:

Showing the most recent 10 out of 747 publications